Cytovia Therapeutics appointed Wei Li as acting chief scientific officer. Li was most recently chief development officer at Korean biotech OliX Pharmaceuticals. Her prior experience includes more than a decade at cancer drug developer Boston Biomedical, where she led development of the company’s lead drug candidate.
New York-based Cytovia is developing cancer immunotherapies based on natural killer cells, a type of immune cell. The company plans to start multiple clinical trials of its “off-the-shelf” treatments in 2021.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
